🏢 官网IRVIRDoubao · 实盘不做把握 9/10不做原因:无增量信息
北京时间·🕒 发布 04:05:00(美东 10-21 16:05)·⟳ 抓取 04:14:15回填·⚡ 决策 10-22 04:29:16·5.5 天前
Vir Biotechnology 宣布将于11月4日举行2026年第三季度财报电话会，未披露任何业绩数据
纯财报电话会日期/接入方式的程序性通知，不含营收、EPS、指引、临床数据或合作等任何方向性增量事实，无法建立多空edge；近72小时多只美股同类Q3电话会日程公告均判定不做，本次结论一致，等待11月4日实际财报再研判。
📄 原文VIR↗ 原文
Vir Biotechnology to Host Conference Call for Third Quarter 2026 Financial Results
SAN FRANCISCO--(BUSINESS WIRE)-- Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that it will host a conference…
不做 Vir Biotechnology, Inc.（VIR.US）
纯财报电话会日程预告（save-the-date），全文无营收、EPS、现金、指引、临床数据或合作等任何增量事实，方向中性、无预期差和交易edge；真正催化在2026-11-04 16:30 ET实际Q3财报及公司更新，届时再研判，不以日程消息提前开仓
展开详情(成交明细 / 研究档案 / 原文全文 / 决策记录链)
研究档案
结论摘要
VIR仅预告11月4日Q3财报电话会时间与直播入口，无任何业绩或经营增量，属例行日程通知；方向中性、无可交易edge，本次不做，待财报实际发布再评估。
🔎 新鲜度:最早出现 2026-10-21 · 扩散 low · price-in 风险 low ↗
主要风险
- 11月4日财报及电话会可能包含管线临床更新或指引，届时才是真实催化，本日程消息本身不构成交易依据
先例如何影响了这次决策
对本次决策的影响:确认本次AVOID，不提前下注，等待11月4日实际财报
方向:无需外部价格先例：本事件不含任何基本面增量，属零催化日程通知，同机制事件（近72小时XRAY、MLM、TRIP、SRI、BBSI、OIS、ALSN、ARDX等Q3电话会日程公告）在本臂历史决策中一致判定不做
涨幅量级:无业绩内容，不具备校准涨跌幅的基础
形态:财报电话会日程预告本身不产生方向性反应，真正波动发生在实际财报发布时
工具执行结果 · 成功 1 · 降级 0 · 失败 0 · 取消 0
- search_processed_events 成功 stock_tools HTTP · 9,577 ms
{"result": "search_processed_events:agent query=`vir biotechnology third quarter 2026 financial results conference call | vir biotechnology 财报电话会 2026年第三季度 | vir q3 2026 earnings call november 4`；结构化索引覆盖完整 72 小时；旧记录兼容扫描近 72.0/72 小时、26838 条本臂决策(完整)，返回 10 条候选。\n• 10-20 20:22 UTC(北京 10-21 04:22) [bm25:
原文全文
展开原文 · 1,387 字
SAN FRANCISCO--(BUSINESS WIRE)--
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, November 4 to provide a corporate update and discuss its financial results for the third quarter ended September 30, 2026. The conference call may be accessed on the
Events & Presentations
page of the Vir Biotechnology website.
About Vir Biotechnology
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN
®
dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
Vir Biotechnology retains exclusive rights to the PRO-XTEN
®
masking platform for oncology and infectious disease. PRO-XTEN
®
is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.
Media Contact
Caren Scannell
Director, Communications
cscannell@vir.bio
Investor Contact
Kiki Patel, PharmD
Head of Investor Relations
kpatel@vir.bio
Source: Vir Biotechnology, Inc.
Vir Biotechnology, Inc. (Nasdaq: VIR), today announced that it will host a conference call at 4:30 p.m. ET / 1:30 p.m. PT on Wednesday, November 4 to provide a corporate update and discuss its financial results for the third quarter ended September 30, 2026. The conference call may be accessed on the
Events & Presentations
page of the Vir Biotechnology website.
About Vir Biotechnology
Vir Biotechnology, Inc. is a clinical-stage biopharmaceutical company focused on powering the immune system to transform lives by discovering and developing medicines for serious infectious diseases and cancer. Its clinical-stage portfolio includes programs for chronic hepatitis delta and multiple PRO-XTEN
®
dual-masked T-cell engagers across validated targets in solid tumor indications. Vir Biotechnology also has a preclinical portfolio of programs across a range of oncologic malignancies. Vir Biotechnology routinely posts information that may be important to investors on its website.
Vir Biotechnology retains exclusive rights to the PRO-XTEN
®
masking platform for oncology and infectious disease. PRO-XTEN
®
is a trademark of Amunix Pharmaceuticals, Inc., a Sanofi company.
Media Contact
Caren Scannell
Director, Communications
cscannell@vir.bio
Investor Contact
Kiki Patel, PharmD
Head of Investor Relations
kpatel@vir.bio
Source: Vir Biotechnology, Inc.
决策记录链 · 只追加
每次领取产生一条记录,重新决策追加一条并以 supersedes 指向被替代的记录(ADR 0014)。
0fbe6e109f· 2026-10-22 04:29 · doubao / doubao-seed-evolving-latest-version · 策略包658c0c1e2ba5当前